Longeveron Inc.

Longeveron Inc.

$4.39
0.5 (12.85%)
NASDAQ
USD, US
Biotechnology

52 Week Range

0.771-37.5

Beta

0.41

Market Cap

$42.2M

Last Dividend

0

PE (TTM)

-0.51

Dividend Yield (TTM)

0

Price Chart

Industry

Biotechnology

Sector

Healthcare

CEO

Mr. Mohamed Wa'el Ahmed Hashad M.B.A.

Full-Time Employees

23

IPO Date

2021-02-12

Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Phone

305 909 0840

Address

1951 NW 7th Avenue, Miami, FL, 33136, US

CIK

0001721484